Sunitinib loaded chitosan nanoparticles formulation and its evaluation

International Journal of Biological Macromolecules

Volumn 82, Issue , 2016, Pages 952-958

  Joseph, Jayapal John ^a   Sangeetha, D ^a   Gomathi, Thandapani ^b  

^a VIT UNIVERSITY   (India)

^b DKM College for Women   (India)

Author keywords

Chitosan nanoparticles; Ionic crosslinking; Sunitinib

Indexed keywords

CHITOSAN NANOPARTICLE; SUNITINIB; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; CHITOSAN; DRUG CARRIER; INDOLE DERIVATIVE; NANOPARTICLE; PYRROLE DERIVATIVE;

ARTICLE; CROSS LINKING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROPHOTOMETRY; X RAY DIFFRACTION; CHEMISTRY; KINETICS; MEDICINAL CHEMISTRY; ULTRASTRUCTURE;

ANGIOGENESIS INHIBITORS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; INDOLES; KINETICS; NANOPARTICLES; PARTICLE SIZE; PYRROLES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84952636494     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2015.10.079     Document Type: Article

References (46)

1. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits c-KIT and platelet-derived growth factor receptor-β in preclinical models of human small cell lung cancer. Mol. Cancer Biol. 2003, 2:471-478.
2. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. Res. 2007, 2:884-896.
3. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 2006, 6:734-745.
4. Britten C.D., Kabbinavar F., Hecht J.R., Li C.L., Bello J., Baum C., Slamon D. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother. Pharmacol. 2008, 6:515-524.
5. Mendel D.B., Laird A.D., Xi X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9:327-337.
6. Gavande Sunil D., Salunke Hemant D., Ughade Prajakta L., Baviskar Dheeraj T., Jain Dinesh K. Biodegradable nanoparticle: emerging research area for novel drug delivery. J. Pharmacy Res. 2012, 5:169-173.
7. Dodane V., Vilivalam V.D. Pharmaceutical applications of chitosan. Pharm. Sci. Technol. Today 1998, 1:246-253.
8. Paul W., Sharma C.P. Chitosan, a drug carrier for the 21st century: a review. STP Pharma Sci. 2000, 10:5-22.
9. Kumar M.N.V.R. A review of chitin and chitosan applications. React. Funct. Polym. 2000, 46:1-27.
10. Roberts G.A.F. Structure of chitin and chitosan. Chitin Chemistry 1992, 1-53. Macmillan, Houndmills. G.A.F. Roberts (Ed.).
11. Chandy T., Rao G.H.R., Wilson R.F., Das G.S. Delivery of LMW heparin via surface coated chitosan/peg-alginate microspheres prevents thrombosis. Drug Deliv. 2002, 9:87-96.
12. Rao S.B., Sharma C.P. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J. Biomed. Mater. Res. A 1997, 34:21-28.
13. Thanou M., Verhoef J.C., Junginger H.E. Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev. 2001, 52:117-126.
14. Wedmore I., McManus J.G., Pusateri A.E., Holcomb J.B. A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J. Trauma 2006, 60:655-658.
15. Sonaje K., Lin Y.H., Juang J.H., Wey S.P., Chen C.T., Sung H.W. In vivo evaluation [1] of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009, 30:2329-2339.
16. Zhang Z., Zhang M., Chen S., Horbett T.A., Ratner B.D., Jiang S. Blood compatibility of surfaces with super low protein adsorption. Biomaterials 2008, 29:4285-4291.
17. Gades M.D., Stern J.S. Chitosan supplementation and fecal fat excretion in men. Obes. Res. 2003, 11:683-688.
18. Tapola N.S., Lyyra M.L., Kolehmainen R.M., Sarkkinen E.S., Schauss A.G. Safety aspects and cholesterol-lowering efficacy of chitosan tablets. J. Am. Coll. Nutr. 2008, 27:22-30.
19. Ragelle H., Vandermeulen G., Preat V. Chitosan-based siRNA delivery systems. J. Controlled Release 2013, 172:207-218.
20. Amidi M., Mastrobattista E., Jiskoot W., Hennink W.E. Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev. 2010, 62:59-82.
21. Konecsni K., Low N.H., Nickerson M.T. Chitosan-tripolyphosphate submicron particles as the carrier of entrapped rutin. Food Chem. 2012, 134:1775-1779.
22. Tan Q., Liu W., Guo C., Zhai G. Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int. J. Nanomed. 2011, 6:1621-1630.
23. Hu B., Pan C., Sun Y., Hou Z., Ye H., Zeng X. Optimization of fabrication parameters to produce chitosan-tripolyphosphate nanoparticles for delivery of tea catechins. J. Agric. Food Chem. 2008, 56:7451-7458.
24. Anitha A., Deepagan V.G., Divya Rani V.V., Deepthy Menon S.V., Nair R., Jayakumar Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate-chitosan nanoparticles. Carbohydr. Res. 2011, 84:1158-1164.
25. Anitha A., Maya S., Deepa N., Chennazhi K.P., Nair S.V., JayakumarCurcumin-loaded R. N,O-carboxymethyl chitosan nanoparticles for cancer drug delivery. J. Biomater. Sci., Polym. 2011, 23:1381-1400.
26. Jang K.I., Lee H.G. Stability of chitosan nanoparticles for L-ascorbic acid during heat treatment in aqueous solution. J. Agric. Food Chem. 2008, 56:1936-1941.
27. Grenha A. Chitosan nanoparticles: a survey of preparation methods. J. Drug Target 2012, 20:291-300.
28. Neves A.L.P., Milioli C.C., Muller L., Riella H.G., Kuhnen N.C.H.K. Stulzer, Factorial design the tool in chitosan nanoparticles by ionic gelation technique development. Colloids Surf. A Physicochem. Eng. Asp., (Print) v. 2014, 445:34-39.
29. Thandapani Gomathi C., Govindarajan H., Rose H.R., Maximas P.N., Sudha P.K., Mohamed Imran, Jayachandran Venkatesan, Se-Kwon Kim Studies on drug-polymer interaction, in vitro release and cytotoxicity from chitosan particles excipient. Int. J. Pharm. 2014, 468:214-222.
30. Bisht S., Feldman G., Soni S., Ravi R., Karikar C., Maitra A., Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin") a novel strategy for human cancer therapy. J. Nanobiotechnology 2007, 5:1-18.
31. Müller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 2001, 47:3-19.
32. Hadjiioannou T.P., Christian G.D., Koupparis M.A., Macheras P.E. Quantitative Calculations in Pharmaceutical Practice and Research 1993, 345-348. VCH Publishers Inc., New York.
33. Bourne D.W.A. Pharmacokinetics. Modern Pharmaceutics 2002, 67-92. Marcel Dekker Inc., New York. 4th ed. G.S. Banker, C.T. Rhodes (Eds.).
34. Higuchi T.J. Mechanism of sustained medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. 1963, 84:1464-1477.
35. Hixson A.W., Crowell J.H. Dependence of reaction velocity upon surface and agitation (I) theoretical consideration. Ind. Eng. Chem. 1931, 23:923-931.
36. Korsmeyer R.W., Gurny R., Doelker E., Buri P., Peppas N.A. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm. 1983, 15:25-35.
37. Liu Y.J., Jiang Y., Feng Y.F., Han D.L. Study on the chitosan hydrolysis catalyzed by special cellulase and preparation of chitooligosaccharide. J. Funct. Polym. 2005, 18:325-329.
38. Vila A., Sanchez A., Janes K., Behrens I., Kissel T., Vila Jato J.L., Alonso M.J. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 2004, 57:123-131.
39. Cheng Y., Samia A.C., Meyers J.D., Panagopoulos I., Fei B., Burda C. Highly efficient drug delivery with gold nanoparticles vectors for in vivo photodynamic therapy of cancer. J. Am. Chem. Soc. 2008, 32:10643-10647.
40. Qi L., Xu Z., Jiang X., Hu C., Zou X. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr. Res. 2004, 339:2693-2700.
41. Wang L., Wang A.Q. Adsorption characteristics of congo red onto the chitelsan/montmorillonite nanocomposite. J. Hazard. Mater. 2007, 147:979-985.
42. Nagini Maganti K.C., Pavan Venkat Surya, Wah Wah Thein-Han C., Thomas Pesacreta R., Misra Devesh K. Structure-process-property relationship of biomimetic chitosan-based nanocomposite scaffolds for tissue engineering: biological, physico-chemical, and mechanical functions. Adv. Eng. Mater. 2011, 13:B108-B122.
43. Zhou S., Deng X., Li X. Investigation on a novel core-coated microspheres protein delivery system. J. Controlled Release 2001, 75:27-36.
44. Peppas N.A. Analysis of Fickian and non-Fickian drug release from polymers. Pharm. Acta Helv. 1985, 60:110-111.
45. Duarte A.R.C., Roy C., Vega-González A., Duarte C.M.M., Subra Paternault P. Preparation of acetazolamide composite microparticles by supercritical anti-solvent techniques. Int. J. Pharm. 2007, 332:132-139.
46. Hintz R.J., Johnson K.C. The effect of particle size distribution on dissolution rate and oral absorption. Int. J. Pharm. 1989, 51:9-17.